Home ›
HER2 Positive Breast Cancer Trials ›
NCT05095207
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Trial Details
NCT ID NCT05095207
Phase PHASE1 / PHASE2
Sponsor Icahn School of Medicine at Mount Sinai
Status RECRUITING
Cancer Type HER2 Positive Breast Cancer
Interventions
Locations (sample) New York, New York, United States|40.71427,-74.00597 New York, New York, United States|40.71427,-74.00597 New York, New York, United States|40.71427,-74.00597
Key Eligibility Criteria
Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses If a patient declines to participate in any voluntary exploratory research and/or genetic component of the study, there will be no penalty or loss … Women aged at least 18 years The patient has a biopsy-confirmed diagnosis of recurrent, unresectable, locally advanced, or metastatic HER2neu-negative breast cancer (including …
For full eligibility, visit ClinicalTrials.gov .